ABP215 is a biosimilar drug developed by Amgen and Allergan, using Avastin (bevacizumab) as a prototype drug. Amgen filed a drug application to the FDA in November 2016. The FDA Oncologic Drugs Advisory Committee (ODAC) met on July 13, 2017, and the members voted in favor of approving the ABP215 drug application. The ABP215 is expected to become America’s first Avastin bio-similar drug. Liu Shining, the research manager in TrendForce,…